| Company Announcements: (reported by the Company) |
No items found
|
| Elevator Pitch: | Lachesis BioSciences is a clinical-stage biotechnology company targeting dementia caused by Alzheimer's and Parkinson's disease. Lachesis Biosciences is developing LBIO-R32, a rivastigmine nasal spray for the treatment of mild to severe Alzheimer's disease dementia and mild to moderate Parkinson's disease dementia. Lachesis is pursuing a 505(b)(2) development pathway for LBIO-R32, which means the company can substantially rely on existing preclinical and clinical data generated by Novartis with rivastigmine for approval. From a development standpoint, this takes years and hundreds of millions off their plate. It's a significantly de-risked and expedited approach. |
| Category: | Hardware & devices, Health & biotech |
| URL: | https://www.lachesisbiosciences.com/ |
| Operational Status: | |
| ASX Listing Code (if applicable): | |
| Year of Commencement: | |
| Address: | 664 Collins St, Level 13, Docklands, Victoria 3008, AU |
| State: | Victoria |
| Overseas Operations: | |
| X: | |
| Facebook: | |
| Linkedin: | https://linkedin.com/company/lachesis-biosciences |
| Founders: |
No items found
|
| Awards won: | |
